Angiogenesis in rheumatoid arthritis

References

• Koch AE. Angiogenesis: Implications for rheumatoid arthritis. Arthritis Rheum 1998; 41: 951–962
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Koch AE. Endothelial cells in inflammation and angiogenesis. Curr Drug Targ 2005; 4: 319–323
   Google Scholar
• Szekanecz Z, Koch AE. Vascular involvement in rheumatic diseases: ‘vascular rheumatology’. Arthritis Res Ther 2008; 10: 224
   PubMed Web of Science ®Google Scholar
• Foster W, Carruthers D, Lip GY, Blann AD. Relationship between endothelial inflammatory and angiogenesis markers in rheumatoid arthritis: Implications for cardiovascular pathophysiology. Thromb Res 2009; 4: 659–664
   Google Scholar
• Szekanecz Z, Koch AE. Mechanism of disease: Angiogenesis in inflammatory diseases. Nat Clin Pract Rheumatol 2007; 3: 635–643
   PubMedGoogle Scholar
• Lainer-Carr D, Brahn E. Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol 2007; 3: 434–442
   PubMedGoogle Scholar
• Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442–447
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Koch AE. Chemokines and angiogenesis. Curr Opin Rheumatol 2001; 13: 202–208
   PubMed Web of Science ®Google Scholar
• Naumov GN, Folkman J, Straume O, Akslen LA. Tumor-vascular interactions and tumor dormancy. APMIS 2008; 116: 569–585
   PubMed Web of Science ®Google Scholar
• Shams N, Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin North Am 2006; 19: 335–344
   PubMedGoogle Scholar
• Jakobsson L, Claesson-Welsh L. Vascular basement membrane components in angiogenesis—an act of balance. Sci World J 2008; 8: 1246–1249
   Google Scholar
• Veale DJ, Fearon U. Inhibition of angiogenic pathways in rheumatoid arthritis: Potential for therapeutic targeting. Best Pract Res Clin Rheumatol 2006; 20: 941–947
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Brenner MB. Role of adhesion molecules in synovial inflammation. Curr Opin Rheumatol 2006; 18: 268–276
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol 2007; 19: 289–295
   PubMed Web of Science ®Google Scholar
• Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, Pope RM, Ferrara N. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994; 152: 4149–4156
   PubMed Web of Science ®Google Scholar
• Kiselyov A, Balakin KV, Tkachenko SE. VEGF/VEGFR signaling as a target for inhibiting angiogenesis. Expert Opin Investig Drugs 2007; 16: 83–107
   PubMed Web of Science ®Google Scholar
• Shibuya M. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep 2008; 41: 278–286
   PubMed Web of Science ®Google Scholar
• Hernandez GL, Volpert OV, Iñiguez MA, Lorenzo E, Martínez-Martínez S, Grau R, Fresno M, Redondo JM. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: Roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med 2001; 193: 607–612
   PubMed Web of Science ®Google Scholar
• Taylor PC, Sivakumar B. Hypoxia and angiogenesis in rheumatoid arthritis. Curr Opin Rheumatol 2005; 17: 293–298
   PubMed Web of Science ®Google Scholar
• Amin MA, Mansfield PJ, Pakozdi A, Campbell PL, Ahmed S, Martinez RJ, Koch AE. Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Arthritis Rheum 2007; 56: 1787–1797
   PubMed Web of Science ®Google Scholar
• Kim HR, Park MK, Cho ML, Yoon CH, Lee SH, Park SH, Leng L, Bucala R, Kang I, Choe J, Kim HY. Macrophage migration inhibitory factor upregulates angiogenic factors and correlates with clinical measures in rheumatoid arthritis. J Rheumatol 2007; 34: 927–936
   PubMed Web of Science ®Google Scholar
• Koch AE, Distler O. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: Rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther 2007; 9(Suppl. 2)S3
   Web of Science ®Google Scholar
• Haq A, El-Ramahi K, Al-Dalaan A. Serum and synovial fluid concentrations of endothelin-1 in patients with inflammatory arthritides. J Med 1999; 30: 51–60
   PubMedGoogle Scholar
• Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99: 11393–11398
   PubMed Web of Science ®Google Scholar
• Manley PW, Martiny-Baron G, Schlaeppi JM, Wood JM. Therapies directed at vascular endothelial growth factor. Expert Opin Investig Drugs 2002; 11: 1715–1736
   PubMed Web of Science ®Google Scholar
• Grosios K, Wood J, Esser R, Raychaudhuri A, Dawson J. Angiogenesis inhibition by the novel VEGF tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis. Inflamm Res 2004; 53: 133–142
   PubMed Web of Science ®Google Scholar
• Kim WU, Kwok SK, Hong KH, Yoo SA, Kong JS, Choe J, Cho CS. Soluble Fas ligand inhibits angiogenesis in rheumatoid arthritis. Arthritis Res Ther 2007; 26: R42
   Google Scholar
• Choi ST, Kim JH, Seok JY, Park YB, Lee SK. Therapeutic effect of anti-vascular endothelial growth factor receptor I antibody in the established collagen-induced arthritis mouse model. Clin Rheumatol 2009; 3: 333–337
   Google Scholar
• Guttmann-Raviv N, Shraga-Heled N, Varshavsky A, Guimaraes-Sternberg C, Kessler O, Neufeld G. Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. J Biol Chem 2007; 282: 26294–26305
   PubMed Web of Science ®Google Scholar
• Fearon U, Veale DJ. Angiogenesis in arthritis: Methodological and analytical details. Methods Mol Med 2007; 135: 343–357
   PubMedGoogle Scholar
• Giatromanolaki A, Sivridis E, Maltezos E, Athanassou N, Papazoglou D, Gatter KC, Harris AL, Koukourakis MI. Upregulated hypoxia inducible factor-1α and -2α pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2003; 5: R193–R198
   PubMed Web of Science ®Google Scholar
• Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G, Cooper M, Laznik D, Chinsomboon J, Rangwala SM, Baek KH, Rosenzweig A, Spiegelman BM. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 2008; 451: 1008–1012
   PubMed Web of Science ®Google Scholar
• Aljada A, O'Connor L, Fu YY, Mousa SA. PPARγ ligands, rosiglitazone and pioglitazone inhibit bFGF- and VEGF-mediated angiogenesis. Angiogenesis 2008; 11: 361–367
   PubMed Web of Science ®Google Scholar
• Bongartz T, Coras B, Vogt T, Schölmerich J, Müller-Ladner U. Treatment of active psoriatic arthritis with the PPARγ ligand pioglitazone: An open-label pilot study. Rheumatology 2005; 44: 126–129
   PubMed Web of Science ®Google Scholar
• Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, Hatae T, Tanabe T, Warner TD, Bishop-Bailey D. Activation of PPARβ/δ induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol 2007; 27: 63–69
   PubMed Web of Science ®Google Scholar
• Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, Park JW. YC-1: A potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003; 95: 516–525
   PubMed Web of Science ®Google Scholar
• Hirota SA, Beck PL, MacDonald JA. Targeting hypoxia-inducible factor-1 (HIF-1) signaling in therapeutics: Implications for the treatment of inflammatory bowel disease. Recent Pat Inflamm Allergy Drug Discov 2009; 3: 1–16
   PubMedGoogle Scholar
• Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ. Vessel cooption, regression and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994–1998
   PubMed Web of Science ®Google Scholar
• Gravallese EM, Pettit AR, Lee R, Madore R, Manning C, Tsay A, Gaspar J, Goldring MB, Goldring SR, Oettgen P. Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha. Ann Rheum Dis 2003; 62: 100–107
   PubMed Web of Science ®Google Scholar
• Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for surviving in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002; 99: 4349–4354
   PubMed Web of Science ®Google Scholar
• Shahrara S, Volin MV, Connors MA, Haines GK, Koch AE. Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue. Arthritis Res 2002; 4: 201–208
   PubMedGoogle Scholar
• Chen Y, Donnelly E, Kobayashi H, Debusk LM, Lin PC. Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction. Arthritis Rheum 2005; 52: 1585–1594
   PubMedGoogle Scholar
• Yoo SA, Yoon HJ, Kim HS, Chae CB, De Falco S, Cho CS, Kim WU. Role of placenta growth factor and its receptor flt-1 in rheumatoid inflammation: A link between angiogenesis and inflammation. Arthritis Rheum 2009; 60: 345–354
   PubMedGoogle Scholar
• Kameda H, Ishigami H, Suzuki M, Abe T, Takeuchi T. Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast-like cells and phosphorylation of Gab adapter proteins activated by platelet-derived growth factors. Clin Exp Immunol 2006; 144: 335–341
   PubMedGoogle Scholar
• Koyama K, Hatsushika K, Ando T, Sakuma M, Wako M, Kato R, Haro H, Sugiyama H, Hamada Y, Ogawa H, Nakao A. Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice. Mod Rheumatol 2007; 17: 306–310
   PubMedGoogle Scholar
• Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D, Chan S-Y, Roczniak S, Shanafelt AB. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995; 270: 27348–27357
   PubMed Web of Science ®Google Scholar
• Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signaling pathway: A molecular hub modulating neo-angiogenesis. Trends Immunol 2007; 28: 299–307
   PubMed Web of Science ®Google Scholar
• Pablos JL, Santiago B, Galindo M, Torres C, Brehmer M, Blanco FJ, Garcia-Lazaro FJ. Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis. J Immunol 2003; 170: 2147–2152
   PubMed Web of Science ®Google Scholar
• Calatozzolo C, Maderna E, Pollo B, Gelati M, Marras C, Silvani A, Croci D, Boiardi A, Salmaggi A. Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas. Cancer Biol Ther 2006; 5: 827–832
   PubMed Web of Science ®Google Scholar
• Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, Murphy WJ. Human endothelial cells express CCR2 and respond to MCP-1: Direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000; 96: 34–40
   PubMed Web of Science ®Google Scholar
• Stamatovic SM, Keep RF, Mostarica-Stojkovic M, Andjelkovic AV. CCL2 regulates angiogenesis via activation of Ets-1 transcription factor. J Immunol 2006; 177: 2651–2661
   PubMedGoogle Scholar
• Volin MV, Woods JM, Amin MA, Connors MA, Harlow LA, Koch AE. Fractalkine: A novel angiogenic chemokine in rheumatoid arthritis. Am J Pathol 2001; 159: 1521–1526
   PubMed Web of Science ®Google Scholar
• Nanki T, Hayashida K, El-Gabalawy HS, Suson S, Shi K, Girschick HJ, Yavuz S, Lipsky PE. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+T-cell accumulation in rheumatoid arthritis synovium. J Immunol 2000; 165: 6590–6598
   PubMed Web of Science ®Google Scholar
• Wente MN, Keane MP, Burdick MD, Friess H, Büchler MW, Ceyhan GO, Reber HA, Strieter RM, Hines OJ. Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett 2006; 241: 221–227
   PubMed Web of Science ®Google Scholar
• Zhang R, Tian L, Chen LJ, Hou JM, Li G, Li J, Zhang L, Chen XC, Luo F, Jiang Y, Wei YQ. Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma. Gene Ther 2006; 13: 1263–1271
   PubMedGoogle Scholar
• Yin Y, Huang L, Zhao X, Fang Y, Yu S, Zhao J, Cui B. AMD3100 mobilizes endothelial progenitor cells in mice, but inhibits its biological functions by blocking an autocrine/paracrine regulatory loop of stromal cell derived factor-1 in vitro. J Cardiovasc Pharmacol 2007; 50: 61–67
   PubMed Web of Science ®Google Scholar
• Madri JA, Williams KS. Capillary endothelial cell cultures: Phenotypic modulation by matrix components. J Cell Biol 1983; 97: 153–165
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Szegedi G, Koch AE. Cellular adhesion molecules in rheumatoid arthritis. Regulation by cytokines and possible clinical importance. J Investig Med 1996; 44: 124–135
   PubMed Web of Science ®Google Scholar
• Imhof BA, Aurrand-Lions M. Adhesion mechanisms regulating the migration of monocytes. Nat Rev Immunol 2004; 4: 432–444
   PubMed Web of Science ®Google Scholar
• Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995; 376: 517–519
   PubMed Web of Science ®Google Scholar
• Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264: 569–571
   PubMed Web of Science ®Google Scholar
• Huang MT, Mason JC, Birdsey GM, Amsellem V, Gerwin N, Haskard DO, Ridley AJ, Randi AM. Endothelial intercellular adhesion molecule (ICAM)-2 regulates angiogenesis. Blood 2005; 106: 1636–1643
   PubMedGoogle Scholar
• Naik TU, Naik MU, Naik UP. Junctional adhesion molecules in angiogenesis. Front Biosci 2008; 13: 258–262
   PubMedGoogle Scholar
• Rabquer BJ, Pakozdi A, Michel JE, Gujar BS, Haines GK, III, Imhof BA, Koch AE. Junctional adhesion molecule C mediates leukocyte adhesion to rheumatoid arthritis synovium. Arthritis Rheum 2008; 58: 3020–3039
   PubMedGoogle Scholar
• Jacq L, Garnier S, Dieudé P, Michou L, Pierlot C, Migliorini P, Balsa A, Westhovens R, Barrera P, Alves H, Vaz C, Fernandes M, Pascual-Salcedo D, Bombardieri S, Dequeker J, Radstake TR, Van Riel P, van de Putte L, Lopes-Vaz A, Glikmans E, Barbet S, Lasbleiz S, Lemaire I, Quillet P, Hilliquin P, Teixeira VH, Petit-Teixeira E, Mbarek H, Prum B, Bardin T, Cornélis F, European Consortium on Rheumatoid Arthritis Families. The ITGAV rs3738919-C allele is associated with rheumatoid arthritis in the European Caucasian population: A family-based study. Arthritis Res Ther 2007; 9: R63
   PubMed Web of Science ®Google Scholar
• Shahrara S, Castro-Rueda HP, Haines GK, Koch AE. Differential expression of the FAK family kinases in rheumatoid arthritis and osteoarthritis synovial tissues. Arthritis Res Ther 2007; 9: R112
   Google Scholar
• Kneilling M, Hültner L, Pichler BJ, Mailhammer R, Morawietz L, Solomon S, Eichner M, Sabatino J, Biedermann T, Krenn V, Weber WA, Illges H, Haubner R, Röcken M. Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice. Arthritis Rheum 2007; 56: 1806–1816
   PubMed Web of Science ®Google Scholar
• McCarey DW, Sattar N, McInnes IB. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?. Arthritis Res Ther 2005; 7: 55–61
   PubMed Web of Science ®Google Scholar
• Skotnicki JS, Zask A, Nelson FC, Albright JD, Levin JI. Design and synthetic considerations of matrix metalloproteinase inhibitors. Ann NY Acad Sci 1999; 878: 61–72
   PubMedGoogle Scholar
• Szekanecz Z, Strieter RM, Koch AE. Cytokines in rheumatoid arthritis: Potential targets for pharmacological intervention. Drugs Aging 1998; 12: 377–390
   PubMedGoogle Scholar
• Brennan F, Beech J. Update on cytokines in rheumatoid arthritis. Curr Opin Rheumatol 2007; 19: 296–301
   PubMed Web of Science ®Google Scholar
• Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE. Evidence of IL-18 as a novel angiogenic mediator. J Immunol 2001; 167: 1644–1653
   PubMed Web of Science ®Google Scholar
• Angiolillo AL, Kanegane H, Sgadari C, Reaman GH, Tosato G. Interleukin15 promotes angiogenesis in vivo. Biochem Biophys Res Commun 1997; 233: 231–237
   PubMed Web of Science ®Google Scholar
• Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α. Nature 1987; 329: 630–632
   PubMed Web of Science ®Google Scholar
• Markham T, Mullan R, Golden-Mason L, Rogers S, Bresnihan B, Fitzgerald O, Fearon U, Veale DJ. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol 2006; 54: 1003–1012
   PubMed Web of Science ®Google Scholar
• Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoskizaki K, Nishimoto N. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003; 48: 1521–1529
   PubMed Web of Science ®Google Scholar
• Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR2-dependent angiogenesis. J Immunol 2005; 175: 6177–6189
   PubMed Web of Science ®Google Scholar
• Fearon U, Mullan R, Markham T, Connolly M, Sullivan S, Poole AR, FitzGerald O, Bresnihan B, Veale DJ. Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. Arthritis Rheum 2006; 54: 3152–3162
   PubMed Web of Science ®Google Scholar
• Amin MA, Volpert OV, Woods JM, Kumar P, Harlow LA, Koch AE. Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ Res 2003; 93: 321–329
   PubMed Web of Science ®Google Scholar
• Morand EF, Leech M, Bernhagen J. MIF: A new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 2006; 5: 399–410
   PubMed Web of Science ®Google Scholar
• Goedkoop AY, Kraan MC, Picavet DI, de Rie MA, Teunissen MB, Bos JD, Tak PP. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy. Arthritis Res Ther 2004; 6: R326–R334
   PubMed Web of Science ®Google Scholar
• Dessein PH, Joffe BI. Suppression of circulating interleukin-6 concentrations is associated with decreased endothelial activation in rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 161–167
   PubMedGoogle Scholar
• Koch AE, Distler O. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: Rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther 2007; 9(Suppl. 2)S3
   Web of Science ®Google Scholar
• Haq A, El-Ramahi K, Al-Dalaan A. Serum and synovial fluid concentrations of endothelin-1 in patients with inflammatory arthritides. J Med 1999; 30: 51–60
   PubMedGoogle Scholar
• Lee MS, Yoo SA, Cho CS, Suh PG, Kim WU, Ryu SH. Serum amyloid A binding to formyl peptide receptor-like 1 induces synovial hyperplasia and angiogenesis. J Immunol 2006; 177: 5585–5594
   PubMedGoogle Scholar
• Mullan RH, Bresnihan B, Golden-Mason L, Markham T, O'Hara R, FitzGerald O, Veale DJ, Fearon U. Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment and matrix degradation in rheumatoid arthritis through an NF-κB-dependent signal transduction pathway. Arthritis Rheum 2006; 54: 105–114
   PubMedGoogle Scholar
• Hong KH, Cho ML, Min SY, Shin YJ, Yoo SA, Choi JJ, Kim WU, Song SW, Cho CS. Effect of interleukin-4 on vascular endothelial growth factor production in rheumatoid synovial fibroblasts. Clin Exp Immunol 2007; 147: 573–579
   PubMedGoogle Scholar
• Haas CS, Amin MA, Allen BB, Ruth JH, Haines GK, III, Woods JM, Koch AE. Inhibition of angiogenesis by interleukin-4 gene therapy in rat adjuvant-induced arthritis. Arthritis Rheum 2006; 54: 2402–2414
   PubMedGoogle Scholar
• Haas CS, Amin MA, Ruth JH, Allen BL, Ahmed S, Pakozdi A, Woods JM, Shahrara S, Koch AE. In vivo inhibition of angiogenesis by interleukin-13 gene therapy in a rat model of rheumatoid arthritis. Arthritis Rheum 2007; 56: 2535–2548
   PubMed Web of Science ®Google Scholar
• Boulday G, Haskova Z, Reinders ME, Pal S, Briscoe DM. Vascular endothelial growth factor-induced signaling pathways in endothelial cells that mediate overexpression of the chemokine IFN-gamma-inducible protein of 10 kDa in vitro and in vivo. J Immunol 2006; 176: 3098–3107
   PubMedGoogle Scholar
• Maurer AM, Zhou B, Han ZC. Roles of platelet factor 4 in hematopoiesis and angiogenesis. Growth Factors 2006; 24: 242–252
   PubMed Web of Science ®Google Scholar
• Vicari AP, Ait-Yahia S, Chemin K, Mueller A, Zlotnik A, Caux C. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol 2000; 165: 1992–2000
   PubMed Web of Science ®Google Scholar
• Woods JM, Mogollon A, Amin MA, Martinez RJ, Koch AE. The role of COX-2 in angiogenesis and rheumatoid arthritis. Exp Mol Pathol 2003; 74: 282–290
   PubMed Web of Science ®Google Scholar
• D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082–4085
   PubMed Web of Science ®Google Scholar
• Komorowski J, Jerczyńska H, Siejka A, Barańska P, Ławnicka H, Pawłowska Z, Stepień H. Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy926 cells. Life Sci 2006; 78: 2558–2663
   PubMed Web of Science ®Google Scholar
• Oliver SJ, Cheng TP, Banquerigo ML, Brahn E. The effect of thalidomide and two analogs on collagen induced arthritis. J Rheumatol 1998; 25: 964–969
   PubMed Web of Science ®Google Scholar
• Rico MC, Castaneda JL, Manns JM, Uknis AB, Sainz IM, Safadi FF, Popoff SN, Dela Cadena RA. Amelioration of inflammation, angiogenesis and CTGF expression ina n arthritis model by a TSP-1-derived peptide treatment. J Cell Physiol 2007; 211: 504–512
   PubMedGoogle Scholar
• Park YW, Kang YM, Butterfield J, Detmar M, Goronzy JJ, Weyand CM. Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. Am J Pathol 2004; 165: 2087–2098
   PubMedGoogle Scholar
• Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348: 555–557
   PubMed Web of Science ®Google Scholar
• Peacock DJ, Banquerigo ML, Brahn E. Angiogenesis inhibition suppresses collagen arthritis. J Exp Med 1992; 175: 1135–1138
   PubMed Web of Science ®Google Scholar
• Hannig G, Bernier SG, Hoyt JG, Doyle B, Clark E, Karp RM, Lorusso J, Westlin WF. Suppression of inflammation and structural damage in experimental arthritis through molecular targeted therapy with PPI-2458. Arthritis Rheum 2007; 56: 850–860
   PubMedGoogle Scholar
• O'Dell JR, Blakely KW, Mallek JA, Eckhoff PJ, Leff RD, Wees SJ, Sems KM, Fernandez AM, Palmer WR, Klassen LW, Paulsen GA, Haire CE, Moore GF. Treatment of early seropositive rheumatoid arthritis: A two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 2001; 44: 2235–2241
   PubMedGoogle Scholar
• Stone M, Fortin PR, Pacheco-Tena C, Inman RD. Should tetracycline treatment be used more extensively for rheumatoid arthritis?. J Rheumatol 2003; 30: 2112–2122
   PubMed Web of Science ®Google Scholar
• Ogrendik M. Effects of clarithromycin in patients with active rheumatoid arthritis. Curr Med Res Opin 2007; 23: 515–522
   PubMed Web of Science ®Google Scholar
• Nemoto K, Mae T, Abe F, Takeuchi T. Successful treatment with a novel immunosuppressive agent, deoxyspergualin, in type II collagen-induced arthritis in mice. Ann NY Acad Sci 1993; 685: 148–154
   PubMedGoogle Scholar
• Bernier SG, Lazarus DD, Clark E, Doyle B, Labenski MT, Thompson CD, Westlin WF, Hannig G. A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. Proc Natl Acad Sci USA 2004; 101: 10768–10773
   PubMed Web of Science ®Google Scholar
• Yin G, Liu W, An P, Li P, Ding I, Planelles V, Schwarz EM, Min W. Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. Mol Ther 2002; 5: 547–554
   PubMed Web of Science ®Google Scholar
• Takahashi H, Kato K, Miyake K, Hirai Y, Yoshino S, Shimada T. Adeno-associated virus vector-mediated anti-angiogenic gene therapy for collagen-induced arthritis in mice. Clin Exp Rheumatol 2005; 23: 455–461
   PubMed Web of Science ®Google Scholar
• Yue L, Shen YX, Feng LJ, Chen FH, Yao HW, Liu LH, Wu Q, Wang H. Blockage of the formation of new blood vessels by recombinant human endostatin contributes to the regression of rat adjuvant arthritis. Eur J Pharmacol 2007; 567: 166–170
   PubMedGoogle Scholar
• Huang XY, Chen FH, Li J, Xia LJ, Liu YJ, Zhang XM, Yuan FL. Mechanism of fibroblast-like synoviocyte apoptosis induced by recombinant human endostatin in rats with adjuvant arthritis. Anat Rec (Hoboken) 2008; 291: 1029–1037
   PubMedGoogle Scholar
• Kurosaka D, Yoshida K, Yasuda J, Yasuda C, Noda K, Furuya K, Ukichi T, Kingetsu I, Joh K, Yamaguchi N, Saito S, Yamada A. The effect of endostatin evaluated in an experimental animal model of collagen-induced arthritis. Scand J Rheumatol 2007; 36: 434–441
   PubMed Web of Science ®Google Scholar
• Kurosaka D, Yasuda J, Yoshida K, Yasuda C, Toyokawa Y, Yokoyama T, Kingetsu I, Yamada A. Kinetics of circulating endothelial progenitor cells in mice with type II collagen arthritis. Blood Cells Mol Dis 2005; 35: 236–240
   PubMedGoogle Scholar
• Sumariwalla PF, Cao Y, Wu HL, Feldmann EM, Paleolog E. The angiogenesis inhibitor protease-activated kringles 1-5 reduces the severity of murine collagen-induced arthritis. Arthritis Res Ther 2003; 5: R32–R39
   PubMed Web of Science ®Google Scholar
• Wang CR, Chen SY, Shiau AL, Wu CL, Jou IM, Chao L, Chao J. Upregulation of kallistatin expression in rheumatoid joints. J Rheumatol 2007; 34: 2171–2176
   PubMedGoogle Scholar
• Mundel TM, Kalluri R. Type IV collagen-derived angiogenesis inhibitors. Microvasc Res 2007; 74: 85–89
   PubMed Web of Science ®Google Scholar
• Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003; 3: 363–375
   PubMed Web of Science ®Google Scholar
• Brahn E, Banquerigo ML, Lee JK, Park EJ, Fogler WE, Plum SM. An angiogenesis inhibitor, 2-methoxyestradiol involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor. J Rheumatol 2008; 35: 2119–2128
   PubMedGoogle Scholar
• Issekutz AC, Sapru K. Modulation of adjuvant arthritis in the rat by 2-methoxyestradiol: An effect independent of an anti-angiogenic action. Int Immunopharmacol 2008; 8: 708–716
   PubMedGoogle Scholar